-
Sector Analysis
NewFrance Life Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
GlobalData’s 'France Life Insurance: Key Trends and Opportunities to 2028’ report provides in-depth market analysis, information, and insights into French life insurance segment. It provides values for key performance indicators such as gross written premium, penetration, and premium ceded and cession rates during the review period (2019–23) and forecast period (2024–28). The report also analyzes distribution channels operating in the segment, gives a comprehensive overview of French economy and demographics, and provides detailed information on the competitive landscape in the...
-
Consumer Insights
NewFrance Retail Consumer Insights – Spending Intentions and Shopping Habits, 2024
This report provides detailed consumer insights into France's retail market. It focuses on the economy, consumer sentiment towards personal finances, cost pressures, offline retail, and online retail. More than half of the French consumers expected the economy to worsen during the first half of 2024. Around 50% of them also expect their finances to deteriorate due to the impact of the economic downturn. French consumers have become wary of non-essential retail purchases. A higher proportion of female consumers in France...
-
Sector Analysis
NewFrance Foodservice Market Size and Trends by Profit and Cost Sector Channels, Players and Forecast to 2028
France Foodservice Market Report Overview The France foodservice profit sector recorded revenue of EUR147 billion ($158.9 billion) in 2023 and is forecast to record a CAGR of over 3% during 2023-2028. Healthy offerings will drive foodservice sales in the profit sector, supported by consumers’ rising health awareness. Vegetarian and vegan diets will gain popularity in the coming years. France Foodservice Profit Sector Outlook 2023-2028, (EUR Billion) Buy the Full Report for More Insights on the France Foodservice Market Forecast Download...
-
Sector Analysis
France Cards and Payments – Opportunities and Risks to 2028
France Cards and Payments Market Overview The annual value of card transactions in the France cards and payments market was $857.59 billion in 2023. The French cards and payments industry is well developed. Multi-functional cards are a prominent feature of the French payment card market. The most common combination is debit and charge card facilities via a single payment card. Additionally, the growing adoption of contactless cards, the expansion of digital-only banks, the emergence of alternative payment solutions, and the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cedazuridine + Decitabine) in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cedazuridine + Decitabine) in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cedazuridine + Decitabine) in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cedazuridine + Decitabine) in Refractory Acute Myeloid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cedazuridine + Decitabine) in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cedazuridine + Decitabine) in Relapsed Acute Myeloid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cedazuridine + Decitabine) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cedazuridine + Decitabine) in Solid Tumor Drug Details: Cedazuridine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cedazuridine + Decitabine) in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cedazuridine + Decitabine) in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cedazuridine + Decitabine) in Triple-Negative Breast Cancer...